During the last session, Sunshine Biopharma Inc (NASDAQ:SBFM)’s traded shares were 0.68 million, with the beta value of the company hitting -1.10. At the end of the trading day, the stock’s price was $3.16, reflecting an intraday loss of -4.24% or -$0.14. The 52-week high for the SBFM share is $780.00, that puts it down -24583.54 from that peak though still a striking 23.42% gain since the share price plummeted to a 52-week low of $2.42. The company’s market capitalization is $3.86M, and the average intraday trading volume over the past 10 days was 0.36 million shares, and the average trade volume was 143.88K shares over the past three months.
Sunshine Biopharma Inc (NASDAQ:SBFM) trade information
Sunshine Biopharma Inc (SBFM) registered a -4.24% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -4.24% in intraday trading to $3.16, hitting a weekly high. The stock’s 5-day price performance is 12.86%, and it has moved by 4.64% in 30 days. Based on these gigs, the overall price performance for the year is -99.58%. The short interest in Sunshine Biopharma Inc (NASDAQ:SBFM) is 0.25 million shares and it means that shorts have 1.67 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sunshine Biopharma Inc (SBFM) estimates and forecasts
Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 111.20% this quarter and then jump 126.80% in the quarter after that. In the rating firms’ projections, revenue will increase 83.00% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 11.8M as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 15.5M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 5.96M and 7.68M respectively. In this case, analysts expect current quarter sales to grow by 98.10% and then jump by 101.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 73.50%. While earnings are projected to return -260.53% in 2024.
SBFM Dividends
Sunshine Biopharma Inc is due to release its next quarterly earnings on 2024-Nov-11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sunshine Biopharma Inc (NASDAQ:SBFM)’s Major holders
Sunshine Biopharma Inc insiders own 0.41% of total outstanding shares while institutional holders control 1.13%, with the float percentage being 1.13%.
